|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.41 / 13.16|
Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study
Triple Combination of PTI-428, PTI-801 and PTI-808 Study to Initiate Dosing in CF Patients in 1H'18
Company to Host Conference Call and Webcast Today at 5:00 p.m. ET
Screening Initiated in Phase 2 Portion of PTI-428 Study, 28-day Dosing Cohort
Updates Announced During the 40th European Cystic Fibrosis Society Conference
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DISCK, FOR, FPI, IAG, TITN Downgrades: PATI, SCKT, TCRD, TRC, UBP Initiations: PTI Read on to get TheStreet Quant Ratings' detailed report:
Insiders at these companies are scooping up shares of their own stock lately.
Levi & Korsinsky, LLP announces that it has commenced an investigation of Proteostasis Therapeutics, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.